Compare Barrick Gold Corp (B) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barrick Gold Corp vs Heron Therapeutics Inc — how do they compare? Barrick Gold Corp trades at $36.15 (market cap $60.50B), while Heron Therapeutics Inc trades at $0.46 (market cap $82.52M). The key difference: Barrick Gold Corp is far larger — about 733.2× Heron Therapeutics Inc's market cap, and Barrick Gold Corp pays a 1.92% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| B | HRTX | |
|---|---|---|
Market Cap | $60.50B | $82.52M |
Sector | Basic Materials | Health |
52-Week High | $52.97 | $2.04 |
52-Week Low | $20.73 | $0.39 |
Enterprise Value | $58.09B | $180.42M |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barrick Mining (B) trades at $35.94, down 2.02% today, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.07, net income margin of 32.14%, and three consecutive quarterly EPS beats. Recent cash flow trends improved significantly, with 2025 net cash flow turning positive at $2.63 billion. The company announced a $0.18 dividend payable in June 2026.
The outlook remains positive given low valuation multiples, robust profitability, and analyst consensus of $52.67 price target. Key risks include gold price volatility and execution of growth projects. With 68% analyst buy ratings and no sell recommendations, Wall Street sentiment supports long-term upside potential despite near-term technical weakness.
HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.
While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
